What is your preferred next line of therapy for a fit patient with unresectable, refractory osteosarcoma who has progressed after MAP, local radiation, and IE?
Would you consider regorafenib based on the REGOBONE trial? Or would you consider other agents knowing that we do not have positive survival data with other regimens?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Emory University
Answered on
- Regorafenib is fine to try. Pazopanib has activity too. I give more pazopanib than regorafenib, so I usually reach for pazopanib first.
- If your patient progressed right through MAP then there is no reason to go back. But if your patient had primary MAP and now, some time later, has progression, yo...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Cancer Care Specialists/Renown Oncology/UNR
Answered on
Cabozantinib also showed activity per CABONE trial. Compares favorably to other TKIs.
Join for free or sign in to see the full answer